Annual SG&A
$11.52 M
-$5.67 M-32.98%
31 December 2023
Summary:
Cardiol Therapeutics annual selling, general & administrative expenses is currently $11.52 million, with the most recent change of -$5.67 million (-32.98%) on 31 December 2023. During the last 3 years, it has risen by +$4.00 million (+53.07%). CRDL annual SG&A is now -48.16% below its all-time high of $22.23 million, reached on 31 December 2021.CRDL Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$7.61 M
+$3.94 M+107.10%
30 September 2024
Summary:
Cardiol Therapeutics quarterly selling, general & administrative expenses is currently $7.61 million, with the most recent change of +$3.94 million (+107.10%) on 30 September 2024. Over the past year, it has increased by +$3.83 million (+101.17%). CRDL quarterly SG&A is now at all-time high.CRDL Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$462.48 M
-$27.81 M-6.40%
30 September 2024
Summary:
Cardiol Therapeutics TTM selling, general & administrative expenses is currently -$462.48 million, with the most recent change of -$27.81 million (-6.40%) on 30 September 2024. Over the past year, it has dropped by -$473.63 million (-4245.48%). CRDL TTM SG&A is now -34915.03% below its all-time high of $22.28 million, reached on 30 September 2022.CRDL TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRDL Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -33.0% | +101.2% | -4245.5% |
| 3 y3 years | +53.1% | +26.6% | -2917.4% |
| 5 y5 years | +154.4% | +336.0% | -5581.8% |
CRDL Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -48.2% | +53.1% | at high | +261.2% | -127.0% | at low |
| 5 y | 5 years | -48.2% | +154.4% | at high | +354.8% | -572.8% | at low |
| alltime | all time | -48.2% | +1256.8% | at high | +3656.0% | <-9999.0% | at low |
Cardiol Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $7.61 M(+107.1%) | $17.99 M(+27.0%) |
| June 2024 | - | $3.68 M(-2.4%) | $14.16 M(+12.5%) |
| Mar 2024 | - | $3.77 M(+28.6%) | $12.59 M(+9.2%) |
| Dec 2023 | $11.52 M(-33.0%) | $2.93 M(-22.6%) | $11.53 M(+3.3%) |
| Sept 2023 | - | $3.78 M(+79.6%) | $11.16 M(-18.0%) |
| June 2023 | - | $2.11 M(-22.0%) | $13.60 M(-10.9%) |
| Mar 2023 | - | $2.70 M(+5.6%) | $15.27 M(-11.5%) |
| Dec 2022 | $17.20 M(-22.6%) | $2.56 M(-58.9%) | $17.25 M(-22.6%) |
| Sept 2022 | - | $6.23 M(+64.9%) | $22.28 M(+1.0%) |
| June 2022 | - | $3.78 M(-19.5%) | $22.07 M(+0.8%) |
| Mar 2022 | - | $4.69 M(-38.3%) | $21.90 M(-1.3%) |
| Dec 2021 | $22.23 M | - | - |
| Dec 2021 | - | $7.59 M(+26.3%) | $22.18 M(+35.1%) |
| Sept 2021 | - | $6.01 M(+66.6%) | $16.42 M(+33.7%) |
| June 2021 | - | $3.61 M(-27.4%) | $12.28 M(+15.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | $4.97 M(+172.5%) | $10.62 M(+42.2%) |
| Dec 2020 | $7.53 M(-4.3%) | $1.82 M(-2.5%) | $7.47 M(+2.1%) |
| Sept 2020 | - | $1.87 M(-4.2%) | $7.32 M(+1.7%) |
| June 2020 | - | $1.95 M(+7.5%) | $7.19 M(-3.5%) |
| Mar 2020 | - | $1.82 M(+8.5%) | $7.45 M(-5.2%) |
| Dec 2019 | $7.87 M(+73.8%) | $1.67 M(-4.1%) | $7.87 M(-6.8%) |
| Sept 2019 | - | $1.75 M(-21.3%) | $8.44 M(+3.0%) |
| June 2019 | - | $2.22 M(-0.5%) | $8.19 M(+26.0%) |
| Mar 2019 | - | $2.23 M(-0.8%) | $6.50 M(+45.2%) |
| Dec 2018 | $4.53 M(+433.2%) | $2.25 M(+49.3%) | $4.48 M(+74.1%) |
| Sept 2018 | - | $1.50 M(+185.8%) | $2.57 M(+87.4%) |
| June 2018 | - | $526.10 K(+159.5%) | $1.37 M(+62.1%) |
| Mar 2018 | - | $202.70 K(-40.4%) | $846.80 K(+31.5%) |
| Dec 2017 | $849.40 K | $340.10 K(+11.9%) | $644.10 K(+111.9%) |
| Sept 2017 | - | $304.00 K | $304.00 K |
FAQ
- What is Cardiol Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Cardiol Therapeutics?
- What is Cardiol Therapeutics annual SG&A year-on-year change?
- What is Cardiol Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Cardiol Therapeutics?
- What is Cardiol Therapeutics quarterly SG&A year-on-year change?
- What is Cardiol Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Cardiol Therapeutics?
- What is Cardiol Therapeutics TTM SG&A year-on-year change?
What is Cardiol Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of CRDL is $11.52 M
What is the all time high annual SG&A for Cardiol Therapeutics?
Cardiol Therapeutics all-time high annual selling, general & administrative expenses is $22.23 M
What is Cardiol Therapeutics annual SG&A year-on-year change?
Over the past year, CRDL annual selling, general & administrative expenses has changed by -$5.67 M (-32.98%)
What is Cardiol Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of CRDL is $7.61 M
What is the all time high quarterly SG&A for Cardiol Therapeutics?
Cardiol Therapeutics all-time high quarterly selling, general & administrative expenses is $7.61 M
What is Cardiol Therapeutics quarterly SG&A year-on-year change?
Over the past year, CRDL quarterly selling, general & administrative expenses has changed by +$3.83 M (+101.17%)
What is Cardiol Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of CRDL is -$462.48 M
What is the all time high TTM SG&A for Cardiol Therapeutics?
Cardiol Therapeutics all-time high TTM selling, general & administrative expenses is $22.28 M
What is Cardiol Therapeutics TTM SG&A year-on-year change?
Over the past year, CRDL TTM selling, general & administrative expenses has changed by -$473.63 M (-4245.48%)